EGFR-TKI rechallenged treatment combined with apatinib in non-small cell lung cancer with EGFR-TKI resistance.

被引：1
|
作者：
Liang, Li
Li, Fang
Cao, Baoshan
Zhang, Zhaohui
Zhu, Xiang
Wang, Jiadong
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e20529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20529
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Analysis of the EGFR mutations in non-small cell lung cancer patients after EGFR-TKI treatment.
    Yamaguchi, H.
    Ikeda, T.
    Tomonaga, N.
    Nakano, H.
    Kitazaki, T.
    Doi, S.
    Nakatomi, K.
    Iida, T.
    Nakamura, Y.
    Kohno, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] The advance of the third-generation EGFR-TKI in the treatment of non-small cell lung cancer
    Cheng, Zhinan
    Cui, Hongwei
    Wang, Yaqi
    Yang, Jin
    Lin, Chunyang
    Shi, Xiaoyu
    Zou, Yuxiu
    Chen, Jing
    Jia, Xiaoqiong
    Su, Liqing
    ONCOLOGY REPORTS, 2024, 51 (01)
  • [23] Evaluation of EGFR degradation as a mechanism of tumor evasion in EGFR-TKI resistant non-small cell lung cancer (NSCLC) cells compared to EGFR-TKI sensitive cells
    Norma, Hernandez-Pedro Y.
    Giovanny, Soca-Chafre
    Mario, Orozco-Morales
    Pedro, Barrios-Bernal
    Oscar, Arrieta
    CANCER RESEARCH, 2018, 78 (13)
  • [24] Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer
    Xu, Yingqi
    Ji, Hao
    Zhang, Yidan
    Xiong, Liwen
    Han, Baohui
    Zhong, Hua
    Xu, Jianlin
    Zhong, Runbo
    ONCOLOGIST, 2024, 29 (07): : e932 - e940
  • [25] Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
    Cao, Peijun
    Li, Yongwen
    Shi, Ruifeng
    Yuan, Yin
    Gong, Hao
    Zhu, Guangsheng
    Zhang, Zihe
    Chen, Chen
    Zhang, Hongbing
    Liu, Minghui
    Pan, Zhenhua
    Liu, Hongyu
    Chen, Jun
    FRONTIERS IN CHEMISTRY, 2022, 10
  • [26] Clinical efficacy of Apatinib combined with Epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) in nonsmall cell lung cancer after EGFR-TKI resistance
    Tian, Ruifen
    Guo, Yi
    Zhang, Xing
    Zhang, Xia
    Song, Xia
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2024, 40 (08) : 1714 - 1718
  • [27] Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
    Tanzawa, Shigeru
    Ishihara, Masashi
    Haruyama, Terunobu
    Ochiai, Ryosuke
    Sakamoto, Takahiko
    Honda, Takeshi
    Ota, Shuji
    Ichikawa, Yasuko
    Watanabe, Kiyotaka
    Seki, Nobuhiko
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (06) : 2223 - 2229
  • [28] The prognosis analysis of EGFR-TKI targeted treatment combined with chemotherapy in smokers with non-small cell lung cancer
    Hong, Guobiao
    Chen, Lijian
    Xu, Jianfeng
    Song, Zhengbo
    Zhang, Yiping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (09): : 13659 - 13668
  • [29] VEGFA mediates traditional EGFR-TKI resistance in non-small cell lung cancer with EGFR exon 20 insertions
    Yang, Yaning
    Liu, Chengming
    Yang, Guangjian
    Xu, Haiyan
    Lei, Siyu
    Wang, Yan
    CANCER RESEARCH, 2024, 84 (06)
  • [30] The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
    Xu Yufen
    Song Binbin
    Chen Wenyu
    Liu Jialiang
    Yang Xinmei
    SPRINGERPLUS, 2016, 5
12345